These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1466 related articles for article (PubMed ID: 34899748)

  • 1. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.
    Santoni M; Massari F; Montironi R; Battelli N
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188547. PubMed ID: 33932561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar.
    Chen K; Liu ML; Wang JC; Fang S
    Biomol Biomed; 2024 May; 24(3):465-476. PubMed ID: 37877819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers.
    Chupradit K; Muneekaew S; Wattanapanitch M
    Cancer Immunol Immunother; 2024 Jul; 73(9):170. PubMed ID: 38954079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances and progress in immunotherapy of solid cancers.
    Kumar A; Emdad L; Das SK; Fisher PB
    Adv Cancer Res; 2024; 164():111-190. PubMed ID: 39306365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor.
    Myers Chen K; Grun D; Gautier B; Venkatesha S; Maddox M; Zhang AH; Andersen P
    Front Immunol; 2024; 15():1380065. PubMed ID: 38726005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.
    Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S
    Front Immunol; 2020; 11():1109. PubMed ID: 32625204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
    Miao L; Zhang Z; Ren Z; Tang F; Li Y
    Front Immunol; 2021; 12():687822. PubMed ID: 34093592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sophisticated genetically engineered macrophages, CAR-Macs, in hitting the bull's eye for solid cancer immunotherapy approaches.
    Unver N
    Clin Exp Med; 2023 Nov; 23(7):3171-3177. PubMed ID: 37278931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils.
    Liang Y; Xu Q; Gao Q
    Front Immunol; 2023; 14():1291619. PubMed ID: 38090576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy.
    Kang M; Lee SH; Kwon M; Byun J; Kim D; Kim C; Koo S; Kwon SP; Moon S; Jung M; Hong J; Go S; Song SY; Choi JH; Hyeon T; Oh YK; Park HH; Kim BS
    Adv Mater; 2021 Oct; 33(43):e2103258. PubMed ID: 34510559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy.
    Li N; Geng S; Dong ZZ; Jin Y; Ying H; Li HW; Shi L
    Mol Cancer; 2024 Jun; 23(1):117. PubMed ID: 38824567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
    Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
    J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
    Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.